Emerging treatments
Combination antifungal therapy
Using 2 antifungal agents from 2 drug classes with different mechanisms of action has not been shown to offer any advantage and should not be considered for most cases with systemic candidiasis. Rare exceptions include patients with mixed Candida species infection or Candida endocarditis.
Anti-candida heat shock antibodies
In one extremely controversial and widely criticized clinical prospective study, some evidence of benefit was suggested when used in combination with a conventional antifungal drug. This product is not available commercially.[56]
Candida vaccine
In mouse candidiasis studies, active immunization seemed to protect infected animals. A number of potential fungal vaccine candidates have reached early human clinical trials.[57]
Rezafungin
Rezafungin, a second-generation echinocandin, has been approved by the Food and Drug Administration for the treatment of candidemia and invasive candidiasis. Results from a phase 3 clinical trial showed that rezafungin was noninferior to the comparator, caspofungin, and demonstrated a similar safety profile.[58]
Use of this content is subject to our disclaimer